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Introduction
Many advances have been made in the study of genetics over the past decade.
The ultimate goal of this research is to develop medical applications which would
provide a cure for the many fatal genetically linked diseases to which conventional
medicine has been only able to alleviate symptoms at best.
The concept of gene therapy is based on a belief that the expression of a
specific amount of functional copies of the mutated gene in the appropriate tissue could
cure the disease. The Genome project is an international quest to map the entire
human genome by the year 2005. This project has proven to be a major step in the
science ofGene Therapy. With the mutated gene responsible for the disease located,
researchers can concentrate their efforts on methods of delivering normal versions of
the gene to the necessary site.
This paper looks at the developments of genetics which have led to the
possibility of medical application. The four diseases illustrated in this paper are among
those at the forefront of genetic research. The illustrations were created with an
editorial purpose in mind. They were designed for a scientific magazine which would
target a general public audience. Each disease is represented by a cover illustration,
as well as a descriptive illustration of the treatment procedure which would accompany
the article. The articles would be part of a four month special focus on research and
developments in gene therapy.
Development of Gene Therapy
Recent clinical trials have brought Gene Therapy into the medical spot light.
This modern answer to medicine actually has a fairly long history. It was born in the
study of genetics, a science concerned with the inheritance of anatomical,
physiological, and behavioral traits. Early founders of genetics were aware of the
possibilities for future medical applications of their discoveries. Expectations and
aspirations for the possible ramifications of this research has created a great interest in
its development. In recent years, much time and effort has been invested in this field of
research.
History
Many fundamentals of genetics developed from a growing interest in inheritance.
One of the leaders in this interest was Gregor Mendel. He is considered the father of
heredity. His research and studies, although viewed insignificant in his lifetime, have
shed much light on the study of genetics. Much of Mendel's recognition is from
experiments in plant hybridization, through his study of the pea plant. Through his
research he had hoped to come to some understanding of the connection between
visible characteristics and statistics of inheritance. This research offered new
understandings of the basis of inheritance. The result of the studies supported
Mendel's beliefs that both parents are responsible for contributions to their offspring.
Prior to this time it was believed that there was a
"blending"
of the two sets of
characteristics with the resulting offspring containing characteristics representing a
means of the two. His explanation for this was that although contributions are received
from both, not all are expressed. The key to this theory was the significance of
dominant and recessive traits. He explained that certain units of inheritance (genes)
are responsible for dictating which traits will be expressed and which ones won't.
The study of genetics is based on the physical expression of molecular makeup,
making understanding at both a micro and macro level essential to its research.
Advances at the micro level began to occur opening new possibilities for the study of
genetics. This new interest let to the development of cell biology. Technology
supportive of this science began to develop, and in 1877 with the aid of more powerful
microscopes, scientists viewed for the first time the fusion of ovum and sperm. As they
studied this event they observed a thread-like structure within the nucleus of the ovum
just prior to its division. This structure was what we now call the chromosome. The
discovery shed a new light on genetic research. The importance of this small strand
was surmised long before its function was fully understood.
In 1892 AugustWeismann, through his study of the relationship between parent
and offspring, proposed that the genetic makeup of the offspring is the result of an
equal contribution from each parent. These new findings made scientists very
receptive ofMendel's work when it was rediscovered in 1900. Questions about
Mendel's work and how certain genes could control the expression of others, lead to
the development of a more specialized field of biochemical genetics.
In 1910 Mendel's Model of genetics was expanded upon, with the discovery that
linked individual genes located on particular chromosomes to certain inherited traits.
Later that year Thomas Hunt Morgan began working on an experiment similar to the
one that Mendel had performed years earlier with the pea plants. Morgan took his work
into the animal kingdom, studying the inheritance patterns of fruit flies. In Working with
the flies he noticed that one of his males had white rather than red eyes which were
normal to this species. His interest in this particular fly led to findings which suggested
the existence of a recessive pattern for this characteristic linked to the male species.
The characteristic visible in the male was expressed only when inherited from the
female. This pattern of inheritance indicated that the gene must be located on the
"x"
chromosome, or is x-linked. This was the first gene that scientists were able to link to a
specific chromosome. Three years later scientists had succeeded in locating the site of
six more genes, thus beginning the science of gene mapping.
Further study of the chromosome led to a deeper understanding of the
interchange of information obtained from a process of crossing over that occurs
between a chromosome pair during sexual reproduction. This interchange of
information is the result of a process called meiosis. The process of meiosis consists of
two consecutive cell divisions resulting in four gametes (daughter cells) containing 23
chromosomes which is one half the number of chromosomes in any cell. When two of
these gametes join in sexual reproduction each contributes its 23 chromosomes
forming a new cell with a complete number of 46 chromosomes. Because of this
process of reproduction the resulting offspring obtain equal contribution from each
parent. This is responsible for the new combinations of hereditary traits. Studying
cross over frequencies has given researchers some insight into the order and
arrangement of the genes. The connection between these two factors is that closer
genes are more likely to cross.
Many discoveries followed in the next few decades. In 1921 one ofMorgan's
students submitted a paper describing the actual makeup and function of the gene.
The significance he suggested was two fold, one being its power to direct organs to
produce specific substances and the second its ability to self replicate. 1940 brought
further insight into the makeup of a gene with the discovery of nucleic acids as the sub
units in genes. Prior to this point the existence of nucleic acids was known but they
were thought to have no noteworthy function. Advances in the understanding of the
function of genes and the roles they play in inheritance continued but their chemical
nature was unknown until 1944. Oswald Avery made this discovery while studying an
earlier theory of transforming principles in the pneumococcus bacteria. He carried out
an experiment in which he selectively destroyed compounds in the bacteria thought to
be possible carriers of genetic information. His observations showed that
transformation persisted in all instances except with the destruction of DNA. This
discovery pointed to DNA as the molecule in which genetic information is stored.
Understanding of the structure of the DNA molecule has also been essential to
genetic research. In 1953 James Watson and Francis Crick proposed a model of DNA
showing its chemical structure. This model described the DNA molecule as long
strands of repeating units. The strands are paired and arranged in a double helix
formation. They consist of configurations of chemical sub units called nucleotides,
which form rung like structures extending perpendicular from one strand to the other.
There are four kinds of nucleotides repeated along the strand, distinguished by their
bases: adenine, thymine, guanine, and cytosine. These bases are the variable part of
the model. Variations in their sequence cause genetic differentiation. The bases are
the sites where the two strands join. They have distinct shapes on their free end which
function like pieces of a puzzle, thus restricting the base that can join with them. For
example adenine can only join with thymine, and guanine with cytosine.
As time went on there grew a greater understanding of genetics. The basic blue
print of life began to be visualized. The human body contains 100 trillion cells, these
membrane bound structures are the sources of chemical reactions essential to
existence. The nucleus of each of these cells contains 46 chromosomes (grouped into
pairs, one from each parent) the chromosomes are filled with tightly coiled strands of
DNA. DNA is made up of smaller segments called genes. The genes contain
instructions to make proteins which are considered the building blocks of life. The
proteins are made up of pairs of amino acids. The nucleus of each of these 100 trillion
cells contains the complete DNAmake up that represents the chemical description of
the individual. Although each cell contains all of the genes they are not all expressed in
each cell. Thus a mutation may occur in every cell but is only noteworthy in that which
it is expressed.
Understanding the regulatory mechanisms of a gene is essential in genetic
engineering. All cells have the same genetic makeup but the genes expressed in each
varies. It is the cell regulators that are responsible for controlling which genes will be
expressed. Because of this the cells can develop into different tissue and take on
special functions. Proteins play an important part in this regulating system, they bind to
a gene and either block its expression or enhance it. The protein blocks expression of
the regulator by processes of repression or attenuation. Repression is a block of RNA
synthesis, and attenuation a halt in RNA synthesis. Expression is enhanced by the
process of activation in which specific proteins are situated near promoters which help
to ensure proper binding of RNA.
Information stored in DNA is transcribed to RNAwhere it is transformed into the
essential proteins necessary for body functions. The sequence of bases on DNA is
transcribed onto a messenger molecule composed of RNA. The messenger RNA
carries the DNA's instructions to a ribosome, which functions as the protein factory
within the cell. The new protein is then released into the cell where it can control the
specific chemical reactions for which itwas designed. Mutations in DNA affects the
amino acid structure which in turn affects the protein. If the structure of the protein is
altered enough it can become inactive. Uncorrected this mutation can be passed from
generation to generation. If the mutation occurs in an essential gene it may result in the
death of the organism.
Genetic disorders
Genetic mutations are permanent changes in the DNA sequence. They can
either be due to single gene disorders, or chromosome disorders in which there is an
excess deficiency of genes in the whole chromosome. There are many opportunities
for genetic error to occur, it is not restricted to the embryonic stages of formation but
poses a threat with each cycle of new cell growth. Disease results when these changes
in the DNA of essential genes reduce its function below the level of that which is
required. The seriousness of a disease is determined by the site of the error.
Single gene defects are the result of base change mutations. These include
the exchange of one base pair for another, the insertion of one or more base pairs, or a
deletion of one or more base pairs. Alterations in nucleotide sequences affect the
amino acid sequence and ultimately affect production of the protein. Mutations can
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occur either spontaneously, resulting from normal cellular operations or they can be
induced by the interaction with different physical agents such as high-energy radiation
and certain chemicals. Such agents are classified as mutagens.
Any base pair of DNA can be mutated. Point mutations are those affecting only
a single base pair. They occur in one of two ways. The most common is through
transition errors in which a substitution of one purine by the other or one pyrimidine by
the other (G-C pair is exchanged with an A-T pair or vise versa). The other is
transversion, which occurs when a purine is replaced by a pyrimidine or vise versa (A-T
pair becomes a T-A pair or a C-G pair). The common cause of transitions mutagens
that interact with one or more base pairs affecting their pairing properties. Another
cause is base mispairing during the normal replication cycle in which the wrong base is
inserted.
Another classification of mutations are insertions/deletions. Insertions of
stretches of extraneous DNA via mechanisms known as transposable elements which
have the ability to move from one site to another. Along with the insertion, deletions of
part of the inserted material or adjacent regions often occur. One major difference
between these insertion/deletions and the point mutations is that the occurrence of
changes caused by transposable elements is not affected by mutagens.
One of the most common periods in which genetic error occurs is during the
process of meiosis. Errors at this time often produce either numerical or structural
abnormalities of the chromosome. The most common and serious type of errors are
numerical abnormalities due to the fact that they directly affect the genome. Only
mutations of the germline can be past to the next generation. The occurrence of these
errors is usually due to nondisjunction, which is the failure of separation between a pair
of chromosomes during the process of meiosis or mitosis. The result of nondisjunction
is either an extra or missing chromosome. Disorders of this type are known as
aneuploidy (abnormal chromosome number) which result in mental or physical mal-
development. Trisomy 21 (Downs Syndrome) is the most familiar disease associated
with this disorder, it is caused by an extra copy of chromosome 13.
Other errors during the process of meiosis cause chromosome abberations result
ing in structural damage to the chromosome. This damage is often in the form of chromo
some breakage due to environmental factors such as radiation, drugs, chemicals, and
viruses. There are several different kinds of errors that fall into this category they include:
Deletion - a section of one chromosome breaks off and its information is lost.
Duplication - a section of one chromosome breaks and attaches to the other chromosome
Inre-rion - a section of one chromosome present in reverse order.
Translocation - a transfer of one chromosome to a chromosome outside of the pair.
Crossing over - segments of a chromosome pair are exchange.
The seriousness of these errors varies. Abberations of chromosome structure,
such as duplications are not as harmful because there is no genetic information lost.
Those causing structural rearrangement on the other hand, such as inversions and
translocations are more serious because they are likely to be transmitted to the next
generation.
The result of these mutations is usually an alteration in the function and stability
of the protein the gene produces. Disease is most often caused by a decrease in
function or stability. It is possible for genetic mutations to enhance the function and
stability however, this is less common and not indicative of a pathological effect.
Proteins are created by the amino acid sequences in a gene. A deletion, addition or
translation of its base pairs can disrupt production of the protein. It does so by
interfering with cellular trafficking. The primary amino acid sequence contains
information which allows it to be recognized by receptors located on the mitochondria
membrane and imported it into the organelle. A change in this sequence makes the
amino acid unrecognizable to the receptor, therefore the protein is never produced.
The severity of the disease caused by these affected proteins depends on the
site and type of the protein. There are two main classes of proteins. The first is called
the "house
keeping"
protein which is present in almost all cells and is responsible for
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maintaining the structure and function of the cell. The second class consists of the
specialty proteins, present in a specific number of cell types and responsible for
carrying out unique tasks. Mutations in the "house keeping" proteins can express itself
in one of several tissues. Mutations of the specialty proteins result in expression of
disease specific to that tissue.
Gene therapy
New understanding of genetics has led to the manipulation of genes, altering an
individual's makeup to elicit desired effects. This procedure has been in use for many
years in the practice of selective breeding. Selective breeding has been common in
agriculture and animal husbandry, but is now being refined to serve medical benefits.
The term genetic engineering first appeared in 1932 in the paper, "Applications of
genetic principles to animal and plant breeding" which was presented before the sixth
International Congress of Genetics. Continuation in this direction offered hope for
applications of gene therapy. Scientists began probing into the relationships between
the damage of DNA and the expression of disease. Studies of the physical expression
of diseases in conjunction with individual genetic make up were conducted. Through
comparisons of the genetic makeup of individuals with and without expression of
specific diseases, they slowly began to discover the site and type of mutation
responsible for many different diseases. The term Gene Therapy refers to the
application of genetic principles to the treatment of disease. With the realized
connection between genetic makeup and the expression of disease it seemed logical to
go directly to the source, correcting the genetic mutation rather than merely trying to
treat symptoms. The basic theory behind this concept is that a functional copy of the
mutated gene when expressed in the appropriate tissue could reverse expression of the
disease. The futuristic ideal hoped to be obtained through genetic research is to some
day be able to diagnose an illness, and treat the patient with the proper portion of
genetic material to cure them.
A great deal of research and efforts have been invested in the development of
such a complex proposal. Such an idea is dependent upon a greater understanding of
the nature and activity of genes including their physical structure. Molecular biology
has played a major role in the visualization of this physical structure. Francis Jacob
and Jacques Monod began studying the expression of genes in bacteria. They
discovered that a cell contains genes for many more functions then it is responsible
for at a given time. Their studies indicated the existence of specialized genes in the
chromosomes that function as a system of genetic regulators. These regulators are
responsible for controlling each cell's function. This regulating system consists of an
operator, responsible for turning on the appropriate genes, a repressor, which sits
on the DNA at specific location and locks the sequence of the genes off, and
operon, which controls the entire coordination sequence of the genes and the
chromosome.
Gene Mapping
There are several common methods of gene manipulation essential to the
practice of gene therapy. They include gene mapping, gene cloning and gene transfer.
Gene mapping and cloning have been essential in the study of genetics and disease.
In order for gene therapy to be considered in the treatment of a disease it is necessary
that the mutated gene first be identified and its site on the chromosome located. Many
advances in gene therapy are the result of this, leading to the ability to culture somatic
cells in the laboratory where they can be closely studied. These studies have provided
answers to the genetic links of many diseases. The identification of genetic mutations
responsible for different diseases makes diagnosis and genetic council possible, and
ultimately aids the development of a cure.
In efforts to advance the possibilities for the application of gene therapy
scientists took on an enormous project 15 years ago of mapping the entire human
genome by the anticipated year of 2005. Through this project genetic engineers are
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striving to decode life's molecular secrets in order to use the knowledge to reverse the
natural course of disease. The medical application of these effort is to use DNA as both
a blueprint for diagnosing the disease as well as a means of correcting the mutation
that make people susceptible to the disease. Their progress has been steady and
many diseases have been mapped at this time. These findings have been invaluable to
the recent progresses made in gene therapy.
GENE SPLICING
Research in gene therapy requires the ability to manipulate a gene, cutting some
segments out and replacing them with others. The problem with this procedure had
been devising an instrument small enough to function at a molecular level. The answer
came in 1960 with the discovery of restricting enzymes. Research showed that foreign
DNA taken in by a bacteria was broken into pieces. Bacteria uses restriction enzymes
to destroy foreign DNA. This is made possible by the presence of a methyl group
(CH3) which helps the cells to distinguish between self and nonself DNA. The
restriction enzymes destroy the virus DNA by cutting specific sequences of bases which
it recognizes as not existing in the bacteria. Over 80 of these "restriction
enzymes"
have now been discovered. These enzymes provide scientists with a method of cutting
specific sequences of DNAwithout destroying the information it carries. Another
feature of this method is that when the restriction enzymes cut the DNA the free ends
has an A, T, G, or C unit without a partner. This is called a
"sticky"
end. Segments cut
with the same enzymes have complimentary sticky ends. These DNA segments look for
complimentary segments to attach to. The benefit of this characteristic is that any new
complimentary DNA sequence introduced after an enzyme has been cut will
automatically join with the cut end.
Gene Cloning
Given the knowledge of the location of a disease's mutation scientists are able to
11
work toward cloning healthy versions of the gene which can be transferred into the
patient to take on its designated function. The process of cloning genes was developed
in 1978. This discovery has made it possible to produce large quantities of genes for
research purposes which has proven essential in advancements of gene therapy. The
first step to cloning a gene is isolating it. This process includes the use of specific
enzymes, like the ones mentioned above, as scissors to cut the DNA into various
lengths. The sequences are then separated with the use of microorganisms (micro
organisms have the ability to recognize specific sequences of DNA, they cleave to them
and then digest them, thus separating them). When all the DNA has been separated
the microorganism containing the segment of interest are broken and the segments
removed. This procedure allows scientists to obtain sequences of interest at
approximately 1 million locations.
Once isolated, itwas then possible to create large quantities of genes that could
be manipulated and studied. Earlier methods relied on bacteria to perform this task.
The process consisted of isolating the gene, and adding it to a collection of bacteria
which were stimulated to multiply. It was successful because bacteria will copy a
human gene just as it copies its own. As scientists began understanding more about
this formation they discovered the entire bacteria was not necessary for the job but
rather specific enzymes within the bacteria called DNA polymerase. These enzymes
use single stranded DNA as templates to make complimentary strands. Although this
was a more efficient way to make copies, its draw back was that it could only copy
single strands, meaning that the double helix had to first be separated. Exposing the
DNA to heat would solve the problem of separating the helix but the amount of heat
needed would also destroy the polymerase. Thus requiring a new batch of bacteria
each time the process was to be repeated. The answer to this problem was to find a
bacteria that was heat resistant and use its polymerase. This characteristic was found
in "hot spring bacteria". The polymerase of this bacteria was accustomed to functioning
at the temperature levels required for separating the helix structure. Today the process
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has been refined the procedure is referred to as Polymerase Chain Reaction (PCR). In
this process the genes are mixed with polymerase enzymes, heated, and then cooled
until the specified number of copies are produced.
Vectors
A common practice in gene therapy includes transferring healthy copies of the
gene responsible for a mutation to the mutation site. The theory behind this is that the
introduction of a healthy gene could take on production of the protein and compensate
for the mutation. This method is most effective in cases which result in under
expression or lack of expression of the protein. In cases where the mutation produces
an over expression of the protein, the mutated gene must be inactivated before the
introduction of the healthy gene. The biggest obstacle at this point in gene therapy is
the development of reliable vectors for transporting the healthy gene. An efficient
vector is essential because the key to this treatment lies in the ability to target a specific
site. Being able to deliver the gene to the site where the genetic mutation is expressed
increases the success rate, and reduces risks of random insertion activating oncogenic
responses. Although there has been progress in the development of vector systems
statistics show that for every gene spliced into the correct place, more than 1000 fit
randomly into the genome.
Refinement of the methods for transferring gene segments has become a very
important consideration in gene therapy. There are several different types of vectors
used for transferring the genetic information including chemical, physical, and viral.
New copies of the healthy gene are introduced into the patient via a vector by one of
two ways either gene replacement or gene integration. Gene replacement, consisting
of a healthy gene being placed into the spot occupied by the mutation. In gene
integration a healthy gene is added anywhere in the genome. The mutated gene is not
removed but the healthy gene is added to compensate for the inadequate protein
production due to the mutation.
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There are several different methods that can be used to transport the genes,
some being more efficient than others. Chemical vectors mix DNA copies containing
healthy genes with a charged substance such as calcium phosphate or certain lipids.
This mixture is dumped into the faulty cell where the chemicals break through the
membrane and transport the DNA inside. This is not an efficient way of integrating the
gene into the genome. Usually only 1 cell in 1000 to 1000,000 will integrate. Physical
vectors involve microinjection with electric shock which make the cells permeable,
allowing entry of the DNA. This method is very efficient in integrating the material into
the genome but the electric shock can cause damage to the cells. The method is also
not as practical because only a single cell can be injected at a time. Viral vectors are
the most common transporters of the genetic information at this time. They are ideal for
this purpose because their natural function is to infect a cell, overtake its nucleus, and
deposit its own contents into it. In the case of gene transfer the virus contents would be
the healthy gene.
Viruses used in gene transfer are disabled so that they will not cause any
harmful effects. The gene responsible for regulating virus replication is removed and
the gene of interest along with its regulators are put in its place. The outer layer of the
virus, however, containing proteins that allow it to take over other cells is left intact. The
result is a structure with all of the infecting properties of a virus but no harmful viral
DNA. The virus deficient of its replicating abilities must then be reproduced in a helper
cell line, which provides the same function as the removed replication regulator. It is
then ready to infect the target cells and insert the healthy gene.
There are several different viruses used for the transfer. They are usually
chosen with consideration of the size of the gene being transferred as well as the type
of gene. The most commonly used viruses are the retrovirus and adenovirus.
Retroviruses are smaller and will only integrate into cells capable of actively dividing.
viral enzymes convert the RNA to DNA, helping it integrate into the genome of the host
cell. Then unable to replicate the virus disappears leaving only the transferred gene
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behind. Integration is not essential to the gene's function, but it offers permanent
expression of the gene even after cell division has occurred. Integrating the gene into
the host's genome is a more beneficial method because it provides long term
expression, but it is also a riskier procedure due to the possibility of the gene integrating
into the wrong part of the genome. Adenoviruses, are larger and have the advantage
of being able to infect both dividing and non dividing cells, but they cannot integrate into
the genome, therefore they only provide short term expression making continual
treatments necessary. The adenovirus enters the host cell by binding to surface
receptors. Once inside the cell it lysis the endosome and releases its own DNA. Both
methods of viral transfer are used in exvivo and invivo procedures. In vitro procedures
like those used in bone marrow transplants require the extraction of the cells,
manipulation of their genes, and then reinjection. In vivo techniques require direct
injection of the viral vector with the healthy gene into the target site.
Illustrations
The format I choose for my illustrations developed out of an interest in editorial
illustration. I chose gene therapy as my topic because it is quickly becoming the future
of medicine. It appears as a recurrent topic in all of the medical/scientific journals. As I
researched the topic I found that the illustrations found in these articles are minimal and
when present they are often only schematic. The illustrations were unappealing and
often intimidating to the average person, full of equations with sequences of letters and
numbers. With the rapid advancement in this line of research and its possibilities as an
effective means of treatment it will not be long before it becomes a very big part of our
medical system. It is important that the general public is made aware of these
advances. As gene therapy is closer to becoming a treatment option there is a growing
need to convey the procedures in a manner appealing to the general public. It was my
desire through this project to design a series of illustrations that would relay the
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necessary information in a simplistic manner that would be understandable to the
general public, and still be interesting enough to attract their attention. I wanted to stay
away from the textbook type of illustrations with molecular models and letter codes.
The illustrations would appear in a general science magazine, such as Discover
or ScientificAmerican. The cover illustrations are used as a means to draw the viewer
in. The focus of these illustrations is on the patient. Using images of the patient offers
the viewer something he or she can relate to and sympathize with, which helps to
personalize the information making it more interesting then a collection of genetic data.
The illustrations were designed to relate to each other, repeating the style and format in
each helps indicate this relationship as a series.
Illustration 1
The introductory illustration for my thesis on Gene Therapy is an
11"X14"
computer generated illustration. It originated from a pencil drawing thatwas scanned
into the computer and colorized in Photoshop 3.0. The illustration was separated into
two layers, the cell and the hand. The DNA molecule was created in Illustrator 5.5 and
the file was brought into Photoshop and placed on a third layer. The layer option was
very helpful in this illustration because it allowed me to rearrange the placement of the
images without losing the information underneath.
I wanted this piece to be more of a conceptual illustration of gene therapy, that
would indicate where this research is headed. I started with a fairly textbook illustration
of a cell with its nucleus and functioning components. I then altered it by adding
familiar surgical elements such as a protractor drawing back the cut nucleus, and a
surgeons gloved hand holding a pair of forceps. The concept behind this illustration
indicates the movement of gene therapy into the practice of common medicine.
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A comparison of
the brain section ofa
Huntington'spatient on
the leftwith a normal
one on the right shows
atrophy ofthe putamen
and caudate nucleus.
The atrophy is a result
ofneuron death linked
to an increased number
ofCAG repeats on the
tip ofchromosome 4.
Huntington's disease (HD) is one of the most
common and serious degenerative diseases of the
central nervous system. This autosomal dominant
x-linked disease expresses itself later in life with
an average course of 15 years until death. The
disease is a result of neuron death in Ihe putamen
and caudate nucleus, two regions of the brain
which control movement. Its victims suffer from
gradual muscle weakness, severe muscle spasms,
chorea, body contortion, and decreased mental
capacity. They eventually face complete muscle
loss making even swallowing impossible.
In 1 983 researchers linked HD to a faulty
gene on chromosome 4. It took teams of
researchers ten years before they were able to
locate this gene. The gene, named IT1 5, was
found on the tip of the short arm of chromosome
4. The mutation is an elongation of the
trinucleotide repeat cytosine, adenine, and
guanine (CAG). The normal IT1 5 gene contains a
repeat sequence ranging from 10-32. Repeats
above this number, usually 32-70, results in the
expression of HD.
These new findings have not provided a cure
at this time, but have led to more effective testing
for the disease. Knowing the location and pattern
of the gene allows researchers to perform
presymptomatic molecular testing for diagnosis.
This has led to a recent discovery of an important
correlation between the number of trinucleotide
repeats and the age of onset. It show patients
with a higher number of repeats to have an
earlier age of expression. It is now possible for
doctors not only to diagnose the disease but also
predict the age of onset.
Huntington's Disease
Huntington's disease is one of the most common serious degenerative diseases
of the central nervous system. It is an autosomal dominant disease that effects 1 in
10,000 individuals. It expresses itself later in life with no hope of treatment. There is no
answer yet through gene therapy but the location of the gene responsible for the
disease has made presymptomatic testing possible.
Huntington's disease (HD) is often referred to as Huntington's chorea from the
Latin meaning dance. It got this name because of the violent choreography of muscle
spasms associated with the disease. Huntington's is a late onset disease, expressing
itself around midlife. The disease results from neuron degeneration and death in the
putamen and caudate nucleus, two regions of the brain involved in controlling
movement. Early symptoms include mood swings, irritability, depression, forgetfulness,
and shortened attention spans. The average course of the disease is 15-20 years
during which time the victim suffers from gradual muscle weakness, severe muscle
spasms, chorea, body contortion and decreased muscle capacity. In the end they face
complete muscle loss making even swallowing impossible.
In 1983 researchers led by Dr. Gussela located a marker for Huntington's on the
short arm of chromosome 4. The presence of the marker indicated that the gene
responsible for HD also resided in this vicinity. However, twenty other versions of the
marker also resided there, complicating the isolation of the HD gene. Researchers
began their search among the 150,000 base pairs located at the tip of chromosome 4,
and continued down the chromosome over a distance of around 2 million nucleotides.
Ten years after the markerwas located researchers were finally abe to isolate the gene
responsible for HD. Huntington's gene, technically known as "IT15", gene was located
on the tip of the short arm of chromosome 4. The mutation expresses an elongation of
the trinucleotide repeat cytosine, adenine, and guanine (CAG). The normal IT15 gene
contains a repeat sequence ranging from 10-32. Repeats exceeding this number,
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usually 32-70 result in the expression of HD.
Researchers discovered that the IT15 gene is expressed in many regions of the
brain in addition to the midbrain as well as different areas of the body such as the
pancreas, colon, testes, and other tissues. Degeneration, however, is restricted solely
to the putamen and caudate nucleus. Not much is known of the biological affects of the
disease and the significance of this repeat. Research indicates that the mRNA
functions properly and is translated into normal amounts of the Huntingtin protein. The
defect appears to be in the protein itself, which can be defective in one of three ways.
First there can be an over activity of the protein. Second an inactivation of its normal
counterpart can cause a reduction or elimination of activity in the Huntingtin protein.
Third the mutation can result from an interaction of the Huntingtin protein with another
cellular component. In the first two cases the Huntingtin protein is directly responsible
for the disease due to a deviation from its normal function. In the third case the normal
function of the Huntingtin protein is being carried out but an additional property acquired
by the protein is responsible for the disease.
Research development for HD is being carried out all around the world.
Researchers have been working closely and collaborating in these efforts. A study was
conducted on 1007 individuals of 43 different national and ethnic groups who
expressed symptoms consistent with those of HD patients. The results showed that
alterations of CAG repeat did not appear to be linked to any specific nationality or
ethnic group. Study of the various cases also indicated that although the disease
usually expressed itself in mid life there were instances where it varied in one direction
or the other. There have been victims as young as 2 and as old as 80. Comparison of
variations in the age of onset with the molecular basis of the disease indicated a direct
connection between the age of onset and the number of CAG repeats. It appeared that
the greater the number of repeats the earlier the disease would be expressed.
These findings made it possible for doctors to perform presymptomatic tests on
individuals at risk of inheriting the disease. Prior to the location of the gene in 1993, 52
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indirect predictive tests and prenatal tests had been performed at the Institute of
Human Genetics. The method of testing at that time relied on analysis of close DNA
markers. This indirect approach required analysis of the patterns of link markers
throughout the families of the individuals at risk. In 1993 with the location of the IT15
gene on chromosome 4, it became possible to directly test the individual to see if
he/she had the excessive CAG repeat indicative of HD. This direct presymptomatic test
for the disease offers many advantages. It is more accurate, more confidential because
it doesn't require family involvement, and it is also not restrictive of individuals who do
not have access to the required family data of indirect testing.
Although the genetic marker linked to HD was discovered in 1983 it wasn't until
1986 that the first presymptomatic testing began. Reservations in going ahead with the
testing were due to ethical and moral concerns. Already a high level of suicide rates
had been connected with HD patients. With the development of direct presymptomatic
tests not only will the individual know if he has the disease but will also receive
indication of when it will begin to express itself. Questions have been raised as to the
benefit of being able to diagnose such a serious degenerative disease to which there is
no treatment. Because of these concerns the testing is not available to everyone, and
when performed is very structured. Some centers require recommendations for
presymptomatic testing. Often contact with genetic councilor, neurologists,
psychiatrists and psychotherapists is required and many of the larger testing centers
provide long term follow ups on their patients as well. Time is also purposely allotted
between the request of the test is requested and its administration because of high
instances of patient withdrawal during this time. These tests are being administered in
centers around the world with over 1500 people tested. This number is significantly
smaller, however, than the number of individuals requesting testing. Reasons for the
difference in numbers are due to either patient reconsideration during pretest
counseling processes, or decline on the part of the doctors.
Although genetics offers no cure for HD to date, it has offered new a
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understanding of the disease. Presymptomatic testing although risky in some aspects
due to the psychological effects is beneficial for family planning because the disease is
often not expressed until well into the child bearing years. In this instance testing can
prevent the passing of the disease to offspring. Doctors have recognized these risks
and testing conditions have been restricted to controlled environments. In the
meantime research on this disease continues in hope that a method for correcting the
genetic mutation lies in the near future.
Illustration 2
The first illustration I did for this project was the cover illustration for Huntington's
disease. It is an 11"X14" acrylic painting on gessoed water color paper. The paintwas
applied in a series of thin washes over a fixed pencil drawing. Decisions were made
about which areas should be opaque and which should bleed through. In the end a fine
grade sand paperwas run over selective areas of the background area to set it back
and add a sense of atmosphere.
I started the illustration by researching the disease and creating a list of common
characteristics expressed by its victims. With this information I began developing
sketches. I decided that the main focus of the illustration would be a portrait, so I
began looking through pathology books for pictures of Huntington's patients. The
reason for the portrait is that it draws the reader in and gives them something the can
relate to. Keeping this idea in mind I chose to illustrate a patient who was not too far
along with the disease. His face although showing some signs of contortion, still
struggles to show the man he use to be, who 5 years earlier may have seemed no
different then you or I. I demonstrated subtle contortion throughout his face to indicate
expression of the disease. The eyes were an ideal site to show contortion, even slight
contortions would be recognized there because it is the place that most people focus.
The eye on the left side of the face is not opened as wide and the lines in the forehead
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above the eye are more compressed. There is nothing relaxed about his face. The
lines in the forehead indicate his strain for control. His mouth is also parched in an
uncomfortable manner.
In the layout the portrait was created large to fill the foreground, so the effects of
the disease would be clearly visible. My aim was to create a layout that would be
visually interesting, to draw the viewer to the article. As a cover illustration it is not
necessary to provide all of the information on the therapy, but attract interest and
arouse enough curiosity to read the article. The DNA molecule adds an interesting
graphic form, which by coming in from the corner draws the eye into the illustration. A
subtle addition of letters on the rungs of the double helix suggest the CAG repeat that is
indicative of the disease. The brain illustration in the lower right shows the site where
the disease is expressed. Although this image is a fairly large element it does not
compete with the portrait because it is a simple outline. Treating the image as an
outline gives enough detail to convey the essential information without being
overbearing. It is less ambiguous as to whether the image is part of the foreground or
background. The decision of placement of the labels also plays a part in drawing the
eye around the bottom of the illustration and backup. The hand-painted type relates to
the treatment of the image of the brain as well as the title. The elements in the piece
integrate well with each other. The use of a mottled background rather than a solid one
makes it easier to unite the figures on it. The neck of the man and the DNA both fade
into the background. Even the use of white type works well, because it is less opaque,
and although readable it blends with the background. There are several elements in
the painting but their treatment makes them easily recognizable as secondary to the
portrait.
Illustration 3
The computer image was created from a finished pencil drawing which was
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scanned into the computer and colorized in photoshop 3.0. To the Photoshop image,
an illustrator 5.5 file of the chromosome was added. The complete illustration was then
brought into Quark 3.32 for layout.
The illustration was designed to be informative yet still aesthetically appealing.
Staying away from solid colors I chose a speckled background, picking up colors from
the cover, and fading it at its upper end. The central focus of this piece is the brain
anatomy. The purpose is to offer a comparison that would show the effect of the
disease in causing atrophy of the brain. I colorized the diseased section and left the
healthy one black and white to demonstrate the comparison more obvious to the
viewer. With no treatment yet discovered for this disease, I focused on the recent
progress in presymptomatic diagnosis, now available through the discovery of the gene
mutation. The illustration again focuses on conveying the mutation of the chromosome
on the left with a red area indicating the site of the mutation and the CAG letters behind
this area indicating the repeat sequence responsible for the disease. These two
graphic elements are treated in such a way that they relate with the other more organic
components of the piece. Radial transparencies were used on the type to fade them
into the background yet still give enough indication of the excessive repeat. The
chromosome is subdued by its color selection. The placement as well as the color of
the chromosome also clearly indicates its relation to the diseased brain section and
therefore its connection to Huntington's. The neuron is added because of its
relationship to the atrophy of the brain. The bend in the neuron draws the eye back
around to the CAG repeat. The purple color used although different from the rest of the
illustration is related back as it picks up tan at the helix of the axon and then turns to
grey as it fades behind the brain section. When the illustration was completed I
dropped shadows behind some of the images to give a sense of spatial variation.
I played with different elements in the layout to make it more interesting. By
moving the illustration to the upper right corner and letting it bleed off the page, I was
able to run the title down the side of the piece in a vertical format. The vertical type
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breaks up the monotony of horizontals. The choice of green type picks up colors from
the illustration and the serif font adds more of an illustrative element. Vertical type is
not always a good choice because it can make reading difficult, but because it was only
used for the title which is a very large font size, it does not become problematic in terms
of readability. The content type of the article is kept very simple using a 10 point Futura
which lines up in two columns under the image. I chose a simple sanserif font because
I didn't want it to compete with the actual page layout making it look too busy. For the
block of type on the right side I chose a times italic to separate it from the body of type
yet relate it to the title.
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9An adenovirus carries
a normal version of the
CFTR gene to the lung
cell epithelium. The
virus binds to the cell's
surface receptors and
invades its nucleus.
Within the cell nucleus,
the CFTRprotein now
takes on thefunction of
a chloride channel.
Cystic fibrosis is the most common fatal
autosomal recessive disease among Caucasians.
The disease's primary site of expression is the
lungs, where a build up of thick mucus clogs the
bronchi making breathing difficult. Chronic
respiratory infection and inflammation eventually
lead to a loss of elasticity in lung tissue. In the
end, the airsacs become unable to extract oxygen
form the air.
In the 1980's, researchers linked the
problem to the means by which water and salt
ions, specifically chloride, pass through the
epithelial cell membrane. Prevention of the
normal flow of salts causes the thick mucus build -
up. In 1 989 the Cystic fibrosis gene was located
on the middle of chromosome 7. It is responsible
for making an important protein called the cystic
fibrosis transmembrane conductance regulator
(CFTR). CFTR acts as a chloride transfer channel,
which is either absent or faulty in cystic fibrosis
patients.
These discoveries opened the door for
treatment with gene therapy. The plan was to
transfer correct versions of the CFTR gene to the
epithelial cells where they could begin functioning
as chloride channels. The adenovirus, a common
cold virus, became the favored vector because it
naturally infects lung cells.
In 1993, Dr. Ronald Crystal preformed the
CFTR transfer on a cystic fibrosis patient.
Adenoviruses carrying copies of the CFTR gene
were dripped down a bronchoscope into the
patient's lungs. The patient's cells soon took on
the production of CFTR. The trial marked a
positive step but can not yet be considered an
effective cure due to the short life of these cells.
Cystic Fibrosis
Cystic fibrosis is the most common fatal autosomal recessive disease among
Caucasians. This common hereditary disease affects around 30,000Americans. The
life expectancy for these individuals is 30 years, which is around twenty years longer
then the average of ten years ago. The discovery of the gene responsible for causing
the disease has opened new doors for treatment with gene therapy.
The disease's primary site of expression is the lungs, where a buildup of thick
mucous clogs the bronchus making breathing difficult. This constant mucous build up
provides an ideal breeding ground for bacteria and infection. Treatment for this has
been pounding on the patient's back to loosen the mucous and dislodge it from the
airways. Antibiotics are also administered to reduce risks of infection. Despite these
efforts patients still suffer from chronic respiratory infection. Inflammation caused by
these infections eventually leads to a loss of elasticity in lung tissue. In the end the air
sacs become incapable of extracting oxygen from the air.
Several other organs are also affected by the disease. As in the lungs a similar
thick fluid builds up at several sites throughout the body blocking small tubes and
causing disfunction of their related organs. In the small tubes of the pancreas build up
of this fluid blocks the flow of digestive enzymes, making patients dependent upon
continual treatment with enzyme supplements to enable them to digest their food. The
fluid building up in the liver clogs the ducts, and therefore poses a threat of organ
failure. In males the vas deferens is a common site for fluid buildup which often leads
to infertility.
The link between the different organs affected is that they all rely on epithelial
tissue. Based on this, researchers searched for a defect linked to the epithelium. The
production of salty sweat as a recurrent characteristic in cystic fibrosis patients led
researchers to take a closer look at the process of chloride ion transport across the
membrane of epithelial cells. In experiments conducted in the 1980's researcher's
25
linked the problem to the means by which water and salt ions, specifically chloride pass
through the epithelial cell membrane. Cystic Fibrosis results when the cystic fibrosis
transport regulator (CFTR) protein is damaged or absent. This defect results in an
unbalanced exchange of ions, with the number of ions leaving the cell being too low.
The ion transfer is directly related to water transfer. Water travels to the site of ion
accumulation to dilute it. In a functioning system greater concentrations of ions are
present outside the cell which draws the water out. With a faulty system in which ions
build up within the cell the water stays inside. Insufficient amounts ofwater transferred
through the cell into the lumen of the related vessels and organs results in an inability to
dilute the fluids produced by the organs. The result of this is a thick mucous build up
and which clogs small passage ways.
Progress began to quicken with greater insight and understandings of the
disease. In 1985 Francis Collins from the University ofMichigan and Lap Chee Tsui
from the University of Toronto began using markers to locate the CF gene. They
isolated the gene between two markers that were located 1 .6 million base pairs apart.
In 1989 they located the gene on the middle of chromosome seven. This gene is
responsible for making the important CFTR protein which is absent or defective in
cystic fibrosis patients. With the gene responsible for the disease located applications
of gene therapy were now a possibility.
Plans for gene therapy began to develop based on a belief that correcting the
gene could cure the disease. One factor that makes cystic fibrosis such a desirable
candidate for gene therapy is that very little of the CF protein is necessary to restore
proper ion transport. This is beneficial to scientists because current methods of
transferring genes are not consistent in directly targeting specific cells.
Inspired byAndrea Pavivani's research of the adenovirus as a vector for
transferring genes, Ron Crystal of the National Heart, Lung and Blood Institute in
Washington DC. began to realize its possibilities in cystic fibrosis. The adenovirus
better known as the cold virus naturally infects lung cells. This invivo approach to gene
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transfer, in which the normal gene is transferred directly into the patient, eliminates the
need for cell extraction and lab culture. Crystal and his colleagues began working on
this concept and developed an adenovirus suitable for the transfer. The virus was
disabled so it would not replicate, and a healthy gene was inserted. On April 17, 1993
Crystal brought this procedure to human trial. Modified adenoviruses carrying normal
copies of the CFTR gene were dripped down a bronchioscope into the patients lungs.
As expected the adenovirus infected lung cells and transported healthy copies of the
CFTR gene to its nucleus where it could theoretically correct the problem.
Crystal has treated several other patients with this technique. He has had
success with all of his patients with the exception of one case which was quickly
rectified. In this case a woman began to express toxic side effects due to too high of a
dose of the virus. There is still some experimentation that needs to be done to find the
balance between too much and too little of the virus. Slight variations of this technique
are being carried out by other doctors. One procedure being performed by Welsh at
the University of North Carolina transfers the virus by dripping it into the patients nose
rather than their lungs. Nasal epithelium appears to produce the same results.
Function of the ion pump is restored. The benefit of targeting nasal epithelium is that it
is more accessible.
There is still much work that must go into developing a more efficient method of
transferring the gene. Although this adenovirus has been successful in restoring
function of the ion pump, it does not integrate into the cell's genome. Because it is not
integrated, after around three months when the epithelial cells are shed the patient
faces the need to repeat the treatment.
iLLUSTfWIONS 4
The cover illustration for Cystic Fibrosis is an
11"X14"
acrylic painting on
gessoed paper. Itwas created in the same style as the previous cover illustrations, by
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thin washes of paint built up over a fixed pencil drawing. I used a rich red for the
background and treated the boy with very warm colors as well. Some of the golden
colors from the DMD piece were also incorporated into this painting.
The portrait for this piece is a child because as I researched the fact that disease
and looked through pathology books most of the patients were children due to the
disease has an early age of onset and shortened life expectancy. I widen the view of
this portrait to include the chest because it is one of the major sites where the disease
is expressed. Outward distortions are seen in the area of the upper chest, exhibiting
what is known as a barrel chest which is a common characteristic among these
patients. Including the chest in my illustration also allowed me to show the inner
expression of the disease. I added a simple schematic illustration over the left side of
his chest to show what occurs in patients with the disease. The lung was also included
to help orient the viewer. The brown accumulations in the bronchus indicates mucous
build up.
In the background I added two chromosomes running vertically down the left
side of the paper. Placement of the chromosomes on the left helps balance the
schematic illustration in the right lower corner. Glowing green sections on the
chromosomes indicate the sight of the mutation. Repetition of the more organic
microscopic views of chromosomes behind the larger graphic one were added as a
design element to fill the space. In deciding on a color for the type I was restricted to
lighter shades because of the dark background. The white that I used in two of my
other pieces would have been too harsh for this one, so I chose to pick up the gold. I
finished the piece by lightly sanding the background to set everything back slightly.
Illustration 5
The computer piece was created in a similar way as the other three, by scanning
a pencil illustrations into photoshop 3.0. The schematic illustration of a chloride
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channel was created in Illustrator 5.5 and imported into Photoshop. In photoshop I
arranged the images on different layers and when the illustration was completed I
brought the file into Quark 3.32 to create the layout.
Using the same type of background as the other computer illustrations I changed
the color to pick up the reds in the painting. The main focus of this illustration is the
bronchus and lung structure because it is the site that the treatment targets. I enlarged
the image of the lungs and bronchi and placed them fairly central on the page to
indicate their importance. The cut section of the right lung allows the viewer to follow
the bronchi as they branch into smaller segments. I continued the branching beyond
what is visible to the eye by adding an inset of the bronchioles with termination at the
aveoli. This shows the site where mucous easily builds and causes obstruction due to
its small size.
The histology plate at the top left corner shows the procedure in which the new
gene is transferred in an adenovirus to the epithelial cells. I faded the edges of the
image into the background to drop it back and reduce competition with the lungs.
Because of the area that this image needed on the left side of the page I shifted the
lungs from a central position to the right slightly. This shift also helped to fill the space
on the right side of the page and while giving a little more space to the side of the
aveoli. The Illustrator file in the upper right corner shows the faulty function of the
mutated gene which is corrected by the transfer. This element works well visually
because it fills the space in the corner without over powering the area. Treating it as a
simple schematic helped to set it back and also allowed me to reduce the size a good
amount without loosing information. I dropped a shadow behind the lungs and inset to
bring them to the foreground and set it apart slightly.
The layout for the piece is similar to the others, the illustration bleeds off the top
right corner, two columns of 10 point futura type lines up under the illustration, and a
small block of 10 point Times italic on the left side describes the illustration. The title of
the article runs vertical up the side and picks up the color of the illustration.
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Blood is drawnfrom
the infant's umbilical
cord, and the stem-
cells are isolated. A
retro-virus is used to
carry a normal copy
oftheADA gene to the
stem-cell's nucleus.
The stem-cells are re
injected into the baby's
blood stream, where
theymigrate to the
bone marrow and take
on the task ofblood
cellproduction.
Severe Combined immunodeficiency (SCID)
is an autosomal recessive disorder, caused by a
blocked production of adenosine deaminase
(ADA), an essential enzyme which breab down
harmful bodily chemicals. The reduction of ADA
leads to a build up of these chemicals, which
poison the immune system's T-cells leaving the
body severely susceptible to disease.
SCID received much recognition in the
1 970's through the tragic story of David, the
famous "bubble boy", who spent the twelve short
years of his life sealed in a plastic enclosure.
Many advances have been made in the study of
genetically inherited diseases, and treatment has
come along way from the plastic bubble. SCID
was the first disease ever treated with human-
gene therapy. In a 1 990 trial, T-cells extracted
from a patient were given normal versions of the
ADA gene via retrovirus vectors and then
reinjected. The success of this procedure was the
T-cell's ability to take on the production of ADA,
enabling the immune system to function properly.
Although an effective treatment, the short life ol
the T-cell would make it necessary to repeat the
treatment every few months.
Searching for a cure, researchers turned
their focus to the stem cells, long-lived precursor;
of all blood cells. Correcting the mutation at this
site would lead to a continual production ol
healthy T-cells. Stem cells, although difficult tc
isolate in adults are plentiful in umbilical core
blood, making this procedure ideal in cases o
prenatal diagnosis.
Severe Combined Immunodeficiency
SCID
Severe Combined Immunodeficiency (SCID) is a rare autosomal recessive
disorder affecting less then 1 in 100,000 people. A common form of this is adenosine
deaminase (ADA) deficiency. The function ofADA is to protect the body from toxic
chemicals that can harm the body's T and B-cells. The result of ADA deficiency is an
extremely low functioning immune system that leaves its victims severely susceptible
disease. New hope for this fatal disease is now under trial with the help of gene
therapy.
SCID received much recognition in the 1970's through the tragic story of David
the famous "bubble boy". The disease expresses itself through constant bouts with
infection. Most patients are diagnosed with the disease by age two, due to continual
trips to the hospital. Children undiagnosed and untreated usually die by the age of one
or two from infection. The only means of treatment had been to create a way to keep
the patient out of contact with germs. This was attempted by sealing them in a sterile
environment. Children like David were often placed inside a small plastic enclosure.
Even the extremity of this method was of little match against the disease. David died
after spending twelve years inside the bubble. Most patients are considered lucky if
they make it to their teenage years. .
The ADA gene is expressed mainly in the thymus and other lymphoid tissue.
ADA is a protective enzyme that restricts the build up of other biochemicals that can
have toxic effects on the body. In the absence ofADA, adenosine, deoxyadenosine
(dADO), and deoxy-ATP builds up in excessive levels in body tissue and fluids. The
excess of dADO inhibits DNA synthesis which leads to cell death. The main site of cell
death is the immune system's T-cell, however B-cells are also affected. The body relies
on the T-cells for protection against antigens. A deficiency or absence of this defense
system leaves the patients severely susceptible to disease making even the common
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cold a life threatening condition.
Science has come a long way since the boy in the bubble. Treatment for the
disease has included bone marrow transplants, enzyme replacement, drugs, and now
gene therapy. Without knowing much about the disease and its causes the only
treatment doctors could offer was isolation, restricting the patient to a sterile
environment to keep the germs away. As researchers began looking forways to treat
the disease bone marrow became an important focus because it is the site of the ADA
production prior to its entrance into the blood stream. Ideas of bone marrow transplant
were suggested but the problem with this treatment is the inaccessibility of compatible
bone marrow. Less then 30% of the patients have a tissue compatible donor. Enzyme
replacement also had its drawbacks in that it can't produce total immune system
reconstruction. Drugs have also been used to stimulate the immune system and
alleviate some of the effects of the disease.
Recently researchers at a biochemical company in New Jersey developed
Adagen, a drug that would simulate the function ofADA. The drug was created by
altering ADA from cows and making it acceptable to humans. Weekly injections of
Adagen were given to a girl suffering from chronic infections due to ADA. The girl's
infections ceased indicating the possibility of a new successful treatment. Upon
continual use ofAdagen however, the drug began to express an inconsistency that
raised questions of its effectiveness. In some instances although their immune system
was enhanced other areas were affected. One child lost the ability to clot normally,
some children got worse and two actually died as a result of the drug. In the last case
the drug stimulated the child's immune system to the degree that it attacked its own red
blood cells. These treatments aimed at alleviating the symptoms and bringing the
patients out of the bubble, were by no means a cure. They required endless trips to the
hospital for repeated treatment with no assurance that each treatment would be
successful. Although the treatments were limited in their effectiveness, the production
of some amount of the missing enzyme is better then none and so treatment continued
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as researchers continued their search for a cure.
New discoveries in the area of genetics has offered new hope for those with
ADA. The first of these was the location of theADA gene. This was found at the tip of
the short arm of chromosome 20. The discovery made it possible for researchers to
clone and study the defect. Researchers held to the belief that if they could replace this
defective gene with a normal version they could cure the disease. Continuation in this
line of research was supported by the refinement of vector systems.
In 1983 efforts went full force. W French Andersen at the National Institutes of
Health (NIH) concluded from his research that ADA was the best disease for testing
gene transfer techniques. Possibilities of using virus vectors were supported by
Richard Mulligan's 1981 experiment involving the successful transfer of human genes
into mouse DNA by mouse leukemia retroviruses. This technique was refined and in
1989 the method was tried in a laboratory on samples of blood from two Ohio girls with
ADA deficiency. Micheal Blaese and Kenneth Culver performed the experiment, using
retroviruses. The viruses carrying normal versions ofADAwere transferred to the girl's
defective blood cells. The result of this landmark experiment was the production of
ADA by the implanted gene.
The success of this experiment led to the first approved human trial of gene
therapy. On September 14, 1990 one of the two Ohio girls, Ashanti Desilva age four
was the first person ever to be treated with gene therapy. Blaese, Anderson and Culver
worked together on this case. They removed the girl's white blood cells and using a
retroviral vector transferred the healthy gene into the cells. The altered cells were then
placed in a plastic bag and were slowly transferred back intoAshanti through an
intravenous tube. The results was positive and on January 30, 1991 the same
treatment was performed on the second Ohio girl, Cynthia Catshalt age four. Cynthia
also showed success. In both cases almost all symptoms of the disease were relieved
and the girls were now even able to leave their houses. The effectiveness of this
treatment will last as long as the new cells circulate in the body. The drawback with
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targeting the white blood cells is that they have a short life span, usually only several
months. Because this is a genetic disease, as the altered cells die the body will
produce new ones using its original genetic plan, thus the patient once again is faced
with an ADA deficiency. Although this trial didn't provide a long term cure it shed new
light on the possibilities of gene therapy. Being able to transfer a gene and having it
take on its programmed function provided hope not only for this disease but other
inherited diseases as well.
Excited by their progressAnderson, Blaese and Culver joined with two blood
experts from NIH, Arthur Nienhuis and Cynthia Dunbar. Their new efforts were based
on the belief that if the gene could be corrected in the stem cells (the precursors of
blood cells) it could produce healthy white blood cells. The advantage of targeting the
stem cells, is that unlike the white blood cells they remain in the body for life. Therefore
correction at this site could permanently rid the patient of the disease. The difficulty of
this method is that the stem cells are not abundant and are difficult to isolate. In May of
1993 Cynthia, one of the Chicago girls was treated by this new method that targeted
the stem cells. Cynthia was given a drug that drew her stem cells out of the bone
marrow into the blood where they could be drawn. The stem cells were then isolated
and normal copies of the gene were transferred to the cells by a retrovirus. The altered
cells were reinjected into the blood stream in hope that they would migrate back to the
bone marrow. The procedure appeared to be a success but their methods of obtaining
the cells still needed some refinement.
Their next efforts were based on the fact that there is one place that the stem
cells are plentiful and that is in umbilical cord blood. A new procedure utilizing the
umbilical blood was quickly developed and brought to trial. Two newborns who had
been diagnosed with having the disease through amniocentesis were ideal candidates.
The first patient wasAndrew Bobea. The moment he was born his umbilical cord was
snipped and blood drawn from it. The blood was sent to the Children's Hospital in Los
Angeles, where Donald Hohn and Kenneth Weinberg isolated the stem cells and
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transferred the new genes. The cells were reinjected back into the infants blood stream
where they migrated to the bone marrow. In the bone marrow the cells appeared to
take on their designated role of producing ADA. The second child to receive this
treatmentwas three-day-old Zachary Riggins. Both cases appeared to be successful.
Scientist are hopeful that this method will provide a cure for those obtaining prenatal
diagnosis. This procedure theoretically should provide long term expression ofADA
with no adverse side affects but only time will tell.
Illustrations 6
The cover illustration for SCID is an 11"X14" acrylic painting on gessoed water
color paper. It was created like the previous ones with a series ofwashes built up over
a fixed pencil illustration. As I began the research of the disease I searched through
books for photos of patients with the disease. The most common one was David the
"Bubble boy". David's struggle with the disease had become fairly well known, he had
even been mentioned in a song by Paul Simon. The public's knowledge of David and
their sympathy for him would make it easier for them to identify with the disease,
drawing their interest to the article.
In the layout of this piece I wanted David to be the main focus bringing him close
to the picture plane, but also indicate his separation from us (the world). The
application of paint in the treatment of David is more opaque and done in a manner that
there is no question that he is the focus of the illustration. There is no visible
indications of the disease so I focused more on portraying the seclusion and separation
of its victims from the outside world. By widening the view and illustrating more then
just his face, I was able to set him back a little from us. This also allowed me to give
some indication of his hands at the bottom of the piece in thick rubber gloves, the only
part of him able to leave the bubble. His head cocked back slightly and turned, with his
eyes looking off also helps separate him. It suggests an unawareness of our presence.
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Transparent white washes were selectively applied over his face to indicate the plastic
bubble. The background was kept subdued using earthy tones with subtle indications
of an environment. This was also set back by rubbing a fine grade sand paper over it.
A stem cell was added in the top right corner to indicate the focus of the new treatments
for the disease. The red blood cells surrounding it act as more of a supportive element.
They help to identify the stem cell, and set it apart from the background which is very
similar in color. Their replication and placement adds a pleasing visual effect. White
hand lettering was used as in the Huntington's piece. It was applied in thin layers
allowing hints of the background to show through.
Illustration 7
The computer piece was created similar to the others in which a black and white
pencil illustration was brought into Photoshop 3.0 and colorized. The colorized file was
then brought into Quark 3.32 for layout. The illustration is more informative then the
cover illustration. It acts as a visual aid, indicating the new methods of gene therapy
being applied to SCID patients as discussed in the article.
I used the same type of background as in the previous piece but modified the
color scheme to pick up the blue tones from the cover illustration. The infant is the
main focus of this illustration showing the new treatments utilizing umbilical blood. Its
large scale and central placement indicate its importance. The treatment is shown in a
series of steps directed by arrows. These steps start with the removal of umbilical
blood with its stem cells, viral transfer to the stem cell nucleus and eventually the return
of the cell to the baby. The arrows used to direct the sequence of the procedure also
play a part in keeping the infant central by their circular formation around his head. The
vertebra section below his foot indicates the success of the treatment with the stem
cell's return to the bone marrow and the production of healthy T-cells. The illustration is
tied together by its movement around the page and variations between foreground and
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background images. Fading images into the background works well in setting them
back, for example the gene transfer procedures above and behind the infant's head
offers enough information to make the procedure clear but doesn't compete with him for
attention. Other images are raised from the background by laying shadows behind
them thus giving a feeling that they are floating.
The page layout follows the same format as the previous ones with the
illustration bleeding off the top corner of the page, two columns of 10 point Futura type
for the body of the article, a small block of 10 point times italic describing the illustration,
and the title running vertically up the left side. The only exception is that this title
includes the full name of the disease. Because of this addition I reduced the size of the
font used on the full name and change it to Futura to prevent it from appearing busy
and hard to read.
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Myoblasts containing
normal copies ofthe
dystrophin gene are in
jected into the patient's
leg muscles.
The myoblasts bind to
thepatient's cells, and
differentiate intomuscle
fibers, capable ofpro
ducing dystrophin.
Duchenne's muscular Dystrophy (DMD) is
the most common inherited skeletal muscular
disease, affecting 70 percent of the body's muscle
cells. It expresses itself early on, causing a
progressive decay of skeletal muscles and a
significant drop in muscle replication. The disease
usually detectable within the first two years,
confines its victims to a wheel chair by age 1 3,
and ends in death by 20.
DMD has been linked to a mutation of the
gene responsible for production of the
cytoskeletal protein, dystrophin. Dystrophin,
present in the muscle sarcolema, functions as an
important structural element to the muscle
membrane. The absence of this protein causes
weakening of molecular connections and eventual
rupture of the membrane due to stress in muscle
contraction.
Experimental treatment for DMD is based
on a belief that the introduction of normal
versions of the dystrophin gene could prevent
expression of the disease. The regenerative
properties of myoblasts, muscle cell precursors,
are ideal for the transferring the gene.
Theoretically the myoblasts would bind to the
patients cells and differentiate into muscle fibers
capable of producing dystrophin.
Dr Peter Law brought this concept to
human trial. He first injected patients with an
immune suppressive drug to prevent cell
rejection. Myoblasts containing the dystrophin
gene were then injected into each of the 22
major muscles of the leg. The patients exhibited
a production of dystrophin, and improved
muscle strength. These results provide hope that
a cure is near.
Duchenne's Muscular Dystrophy
DMD
Duchenne's Muscular Dystrophy (DMD) is the most common inherited skeletal
muscular disease affecting more than 1 in 3500 males. It is an X-linked recessive
disease causing deterioration of 70 percent of the body's muscle cells. It is expressed
early on, usually detectable by the time the child begins to walk. From this point there
is a progressive decay of skeletal muscles. A significant drop in muscle replication is
evident by age 2. The disease usually confines its victims to a wheelchair by age 13
and results in death by age 20. Progress in genetic research offers new hope for these
patients. The discovery of the gene responsible for causing the disease has made
experimentation with gene therapy possible.
In 1987 Koening identified the sequence of the gene affected in DMD patients,
this is the largest sequence identified in the human genome to date. The gene is
responsible for the coding of a rod-shaped protein, called dystrophin. DMD was the
first type ofmuscular dystrophy whose mutated gene was cloned and the protein it
codes for identified. The discovery has led to more concentrated research of the
disease, making it the most focused on of muscular diseases. 60 percent of
individuals expressing symptoms of DMD exhibit a deletion in the dystrophin gene, and
5 percent show a duplication mutation. Mutation of the gene is usually the result of a
stop codon which causes premature termination of the polypeptide and affects the
production of dystrophin. The dystrophin protein present in the muscle sarcolema,
functions as an important structural element of the muscle membrane. The absence of
this protein causes a weakening of molecular connections and eventual rupture of the
membrane during the stress of muscle contraction. Cell death is easily detectable by
measuring the levels of an enzyme called creatine kinase in the blood. Small amounts
of this enzyme, responsible for maintaining muscle energy levels is normally detectable
in the blood. It is released in large amounts in DMD patients leaking from the muscle
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tissue being broken down.
The severity of this disease, forwhich there had been no adequate treatment
and no hope of stabilization or improvement, has made it a major interest in genetic
research. The development ofmouse and canine models has provided much insight
into the possibilities of gene therapy treatments for the disease. The mice studied have
been bred with simulated DMD, showing no expression of dystrophin in skeletal and
cardiac muscle. The muscles of these mice began to show signs of necrosis and
regeneration leading to centralized nuclei in the majority of muscle cells. The
centralized nuclei indicate ongoing muscle degeneration and regeneration. After 20
days atrophy and fibrosis similar to that of DMD patients occurred. The difference in
the mice however, was that they demonstrate no weakness. The mouse model offers
an accurate simile of the disease's chemical and genetic expression but it differs in its
physical expression. Dogs used in the canine models do not contain dystrophin, exhibit
muscularweakness, similar to that expressed in humans. Using these two models
researchers began experimenting with gene therapy for methods of curing the disease.
Experimental treatment for DMD was based on a belief that the introduction of a
normal version of the dystrophin gene could prevent expression of the disease. One
important consideration in these experiments was the size of the dystrophin gene. The
full length of the gene was too large to be carried in the common adenoviral or retroviral
vectors. To get around this problem minigenes were created thatwere short enough in
length to fit in the virus, yet retained the information necessary to produce dystrophin.
Based on this model, two human minigenes were created for experimentations in gene
transfer. In a series of these experiments copies of the minigene were injected into
fertilized mouse ova that had inherited the defective dystrophin gene. As the cells
multiplied so did the correct copy of the gene so that itwas expressed in every cell of
the body. As a result the mice were born with no expression of the disease. This study
provided hope that the transfer of correct versions of the dystrophin gene can relieve
the expression of the disease. Their theory was supported by the expression of
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dystrophin in the sarcolemal membrane, decrease in the number of fibers with
centralized nuclei, and restoration of dystrophin associated proteins. Similar
techniques were performed in canine experiments in which researchers were able to
get a better idea of the experiments effects on the phenotype.
With indications that a transfer of a healthy gene to the cells could cure the
disease, methods of transferring the gene to the appropriate cells because the biggest
dilemma. Successful gene transfer for human trials requires that the normal versions of
the gene be transferred to at least 70 percent of the muscle cells in the body. This
statistic rules out direct injection as an effective method because the cells would only
be expressed at the site of the injection. Viral vector systems which can transport
truncated versions of the gene are more efficient. A retrovirus could only be be used to
transfer the gene into myoblasts because they infect dividing cells . The myoblast
would then have to be transferred to the muscle. Adenoviruses, on the other hand, do
not require cell division and can transfer the truncated gene directly to the muscle.
The current procedure for the therapy includes the use of the myoblasts (muscle
precursor cells). The new vector system utilizes the regenerative property of myoblasts
to deliver the functioning dystrophin gene to the muscle. Theoretically, the muscle cells
produced by the myoblast would fuse to the patients muscle and each other, and the
new cells would be equipped to produce the dystrophin needed to strengthen the
muscles. Results indicate that the new cells were producing the needed dystrophin but
the dystrophin expression was short lived.
Human trials for the treatment of gene therapy on DMD patients is being
performed at several centers throughout the world. One of the leaders of this treatment
is Dr. Peter Law, director of the Cell Therapy Research Foundation in Memphis. Using
a myoblast transfer method, Law performed the procedure on 24 DMD children. The
children were first injected with cyclosporine, an immune suppressive drug to reduce
rejection of the transfer. Myoblasts containing the normal dystrophin gene were
collected from healthy individuals. Five billion of the healthy cells were injected into
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each of the 24 major muscles of the leg of each child. The patients treated began to
exhibit a production of dystrophin and increased muscle strength. 81 percent of the
injected muscles appeared to get stronger, some patients, who were wheelchair bound
prior to the expression, were even able to walk . The drawback to this method
however, is that repeated injections could have an adverse effect, weakening the
already affected muscles.
Therence Partridge of London's Caring Cross Hospital performed a variation of
this experiment in which he used myoblasts extracted from DMD patients. The
myoblasts were injected with normal copies of the gene. The cells were multiplied in
culture, and then reinjected. His results were similar to Law's but, he observed that the
dystrophin was only expressed local to the site of injection. In order for complete
muscle restoration injections would have to be given all over the body and repeated
injections may also be required. Injection into the blood stream would solve the
problem of localization of the cells. Experiments of this type however, show that the
cells have a difficult time leaving the blood and entering the muscle. Patridge is
currently working on engineering cells that would have similar characteristics as the
white blood cells in their ability of leaving the blood stream and attaching to muscle in
immune system responses.
There still is no effective treatment for DMD but greater understanding of the
disease and experimentation and trials with gene therapy offer a new hope for these
children.
Illustrations 8
The cover illustration for Duchenne's Muscular Dystrophy is an
11"X14"
acrylic
painting on gessoed paper. Itwas created in the same style as the previous cover
illustrations, by building up washes over a fixed pencil drawing. Keeping with a similar
color scheme as the previous pieces I chose earthy tones of gold and brown for the
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background and repeated them in the figure as well.
I began collecting information on the disease and looking for photo sources,
most ofwhich were young boys due to the early expression of this X-linked disease.
One of the main sites of expression of the disease is the leg muscles so many of the
sources showed full body shots of the boys. I wanted to stick with the idea of keeping
the illustration more personal. Coming in closer on the patient makes it a little more
intimate and easier for the viewer to relate to the patient, thus creating an interest.
Showing the full figure would set the image back too far, making it seem more like a
case study. I did decide to widen the the view a little to include the shoulders and
chest. The strain in the neck and shoulders gives some indication of the loss of muscle
control. Although I widened the view one factor that helps to keep the image up front is
the boys eyes, they stare right out at you and helping to draw the viewer in.
I used sketchy schematic figures along the bottom of the illustration to provide
the information lacking in th portrait. These types of figures appeared in most of the
material I researched. The figures show the steps the patients go threw in standing up.
This four or more step process is common among all DMD patients because they don't
have the leg strength to pull themselves up the way most people do. No more
information then an outline is necessary to convey the information and the outline works
well with the piece because it allows the background to show through so as not to
compete with the portrait. The image in the upper right corner is a histology plate of
muscle. I added this more as a design element then a source of information. It fills the
area nicely forming an interesting pattern. I chose a palette of browns for the muscle so
that it would not become to heavy in the corner, this also made it easy to fade into the
background. Because of the light gold background I choose a darker color for the type.
To break the monotony of browns I used a rich green. The green was applied in a
similar manner as in the previous illustrations with thin washes so that some of the
information behind was allowed to show through. When the painting was complete I
went over it with a fine grain sand paper to unite it. The boy was left untouched
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keeping him the focal point.
Illustration 9
The computer piece was created the same way as the previous ones by
scanning a black and white pencil illustration into Photoshop 3.0 and colorizing it. The
colorized file was then brought into Quark 3.32 to create the layout. The images were
placed on different layers to give more of a sense of depth and make them easier to
work with.
I used the same type of background as in my previous computer pieces but
changed the colors to pick up the golden browns from the painting. The illustration is
meant to show the procedure of myoblast transplants which focuses on the leg muscles
of DMD patients. I made the leg a major element of the illustration by increasing its
size and bringing it to the foreground. The other essential element in this procedure is
the myoblast containing the healthy dystrophin gene being transferred. The three
myoblasts in the upper right corner were added as an aesthetic decision. One
myoblast due to its long thin shape seemed to get lost in the corner, and enlarging it
competed too much with the leg. Angling one myoblast helps break the verticals and
draw the eye around. The layout helps to direct the viewer through the sequence of the
steps in the procedure, from the myoblast to the hypodermic needle to the leg. The
muscle bundle coming out of the leg helps to orient the viewer between the gross view
and the microscopic, where the process is being carried out. I used extreme
foreshortening because of the small size of the myofiber. It also helps in drawing the
eye to the lower right section of the illustration. The image of the fibers in the lower
right show the results of the procedure with myoblasts containing the healthy gene
migrating and forming new muscle fibers. I dropped the image to the background to
give some depth variation. The fiber crossing over it allows enough information to be
seen for it to be identifiable without over emphasizing it. The cross section of muscle
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fibers above it that fade into the background were an aesthetic decision to help unite
the information.
The layout for the piece is similar to the others, the illustration bleeds off the top
right corner, two columns of 10 point futura type lines up under the illustration, and a
small block of 10 point Times italic on the left side describes the illustration. The title of
the article runs vertical up the side, using a sanserif and smaller font size for the full
name of the disease to make it more readable.
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